N-myc suppression and cell cycle arrest at G1 phase by prostaglandins  by Marui, Nobuyuki et al.
Volume 270, number 1,2, 15-18 FEBS 08828 September 1990 
N-myc suppression and cell cycle arrest at G1 phase by prostaglandins 
Nobuyuki Maruil, Toshiyuki Sakail, Nobuko Hosokawal, Mitsunori Yoshidal, Akira Aoikel, 
Keiichi Kawa?, Hoyoku Nishino2 and Masanori Fukushima3 
Departments of ‘Preventive Medicine, and 2Biochemistry, Kyoto Prefectural University of Medicine, Kbmikyo-ku, Kyoto 602, Japan 
and 3Department of Internal Medicine, Aichi Cancer Center, Chikusa-ku, Nagoya 464, Japan 
Received 7June 1990; revised version received 17 July 1990 
Effects of cyclopentenone prostaglandins, di*-prostaglandin (PG) JI and PG4 on the expression of N-myc in relation to the effects on cell cycle 
progression were investigated using human neuroblastoma cell line GOTO. Both PGs suppressed N-myc expression within several hours prior to 
inducing G1 arrest. The N-myc suppression with &*-PGJ, was continued but with PG4 it was gradually released, followed by the release of G, 
arrest. These results suggest hat diz-PGJ, and PG4 inhibit cell cycle progression in strong association with N-myc suppression and di*-PGJ, 
is more potent and has a longer effect than PG4. 
d12-Prostaglandin J,; Prostaglandin 4; N-myc; Cell cycle; Human neuroblastoma cell 
1. INTRODUCTION 
Cyclopentenone prostaglandins (PGs), A12-prostag- 
landin J2 (A”-PGJ2) and PGA2 are active metabolites 
of PGD2 and PGE2, respectively [1,2]. They act directly 
on nuclei and arrest the cells at the Gr phase of cell cycle 
[3,4]. The inhibitory effect on cell cycle progression of 
Ar2-PGJ2 is somewhat irreversible, whereas that of 
PGA2 is reversible [4]. Though the precise mechanisms 
of the cell cycle arrest induced by PGs are still not 
known, using human promyelocytic leukemia cell line 
HL 60, Ishioka et al. reported that PGAz suppresses c- 
myc expression completely prior to the cell cycle arrest 
and the effects are reversible [5]. Here we report that 
A12-PGJ2 and PGA2 suppressed N-myc mRNA expres- 
sion in human neuroblastoma GOT0 cells whose N- 
myc is amplified and that the suppression and the 
restoration of N-myc were closely associated with the 
changes of cell cycle progression. 
Tokyo, and fetal calf serum (FCS) from Flow Laboratories, North 
Ryde. RNase A was obtained from Sigma, St Louis, MO. Propidium 
iodide was obtained from Calbiochem Corp., La Jolla, CA. [a-“PI- 
d CTP was obtained from Amersham Japan. All other chemicals used 
were of reagent grade. 
2.2. Cell culture 
Human neuroblastoma cell line GOTO, established by Sekiguchi et 
al. [6], was used. Cultures were maintained in DMEM containing 
10% FCS and were incubated at 37°C in a humidified atmosphere of 
5% CO2 in air. Cells were seeded at 0.5 x 10’ cells/ml in a total 
volume of 4 ml onto 60 mm 0 dishes for cell cycle analysis and 
Northern blot analysis. The medium was renewed 2 days after inocu- 
lation and PGs were added at various concentrations. 
2.3. Flow cytometric analysis 
2. MATERIALS AND METHODS 
Cells were removed at the indicated time from culture dishes by 
trypsinization and centrifuged. After washing twice with phosphate- 
buffered saline without Ca2 ’ or Mg2 + (PBS ( - )), they were suspend- 
ed in PBS (- ) containing 0.1% Triton X-100. Then the suspension 
was filtered through 50 q nylon mesh and incubated with 0.1% 
RNase and 50 pg/ml propidium iodide for 30 min. DNA contents in 
stained cells were analyzed with FACScan, Becton Dickinson. The 
suspension of 1 .O x 104 cells was analyzed for each DNA histogram. 
Cell numbers in each phase were measured according to the S fit pro- 
gram in the FACScan [7]. 
2.1. Chemicals 
PGAr was purchased from Funakoshi Chemicals Co., Ltd., 
Tokyo, and Ai2-PGJr was a kind gift from Fuji Pharmaceutical Co., 
Ltd., Toyama and from Ono Pharmaceutical Co., Ltd., Osaka. PGs 
were dissolved in absolute ethanol and stocked at a concentration of 
10 mg/ml at - 20°C and were diluted to appropriate concentrations 
at the time of use. The final concentration of ethanol used to dissolve 
PGs was less than 1 .O%. Each equivalent ethanol was added to con- 
trol dishes and it had no effects on GOT0 cells. Dulbecco’s modified 
Eagle medium (DMEM) was obtained from Nissui Seiyaku Co., Ltd., 
2.4. Northern blot analysis 
Correspondence address: N. Marui, Department of Preventive 
Medicine, Kyoto Prefectural University of Medicine, Kawaramachi 
Hirokoji, Kamigyo-ku, Kyoto 602, Japan 
Total cellular RNA was prepared by the acid guanidium 
thiocyanate-phenol-chloroform extraction as described by Chomc- 
zynski et al. [8]. Each total cellular RNA (3 pg) sample was denatured 
and electrophoresed and then transferred to a Nitro Plus 2000 mem- 
brane purchased from Micron Separations Inc., Westboro, MA. 
After prehybridization, hybridization was performed as described 
before [9]. Hybridization probe was 1 .O kb &oRI/BamHI fragment 
(Nb-1) from human neuroblastoma cell line Kelly [lo] and actin probe 
was used as an internal control [ll]. Both probes were purchased 
from Oncor, Gaithersburg, MD. Probes were labelled with [cr-32P]d 
CTP to a specific activity of > 10s cpm/pg by nick translation. The 
filter was exposed to Fuji RX film. The autoradiograph was scanned 
by densitometric tracing, CS-9000 from Shimadzu Co. Ltd., Kyoto. 
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Fig. 1. Dose-dependent effects of Ar2-PGJz (A) and PGAr (B) on cell cycle progression. After 24 h from the addition of PGs, the percentages of 
Gr (o), S ( A ), and G2 + M ( q ) phases were obtained by flow cytometric analysis. 0 kg/ml represents control culture without PGs. DATA are shown 
as means + SD (n = 5 for Ar2-PGJ2, n = 4 for PGAz). 
3. RESULTS 
3.1. Effects of PGs on cell cycle progression 
To investigate the effects of PGs on the cell cycle pro- 
gression of GOT0 cells, we treated cells with PGs after 
2 days of inoculation. At 24 h from the addition of 
PGs, DNA contents of the cells were measured by flow 
cytometric analysis. As shown in Fig. 1, the peaks of Gi 
phase cell accumulation were obtained with 2.5 pg/ml 
(7.5 PM) of Ai2-PGJ2 and 7.5 pg/ml (22.4 PM) of 
PGA2, respectively, at which doses the cells remained 
viable. The growth curves of GOT0 cells (data not 
shown) showed that the I& value of A12-PGJ2 was 2.5 
pg/ml and of PGA2 between 7.5 pg/ml and 10.0 pg/ml. 
At higher doses, the percentages of Gr cells were similar 
to those of the controls, and the PGs completely in- 
hibited the cell growth of GOT0 cells. So we made 
following experiments with 2.5 pg/ml of A12-PGJz and 
7.5 pg/ml of PGA2, which arrested the cell cycle 
specifically in Gi/S boundary. Fig. 2 shows DNA 
histograms at 24 h, the percentages of Gi phase cells in- 
creased, whereas those of S phase cells decreased. These 
suggest that PGs blocked the cell cycle at the Gi/S 
boundary as mentioned before [4,12]. Next we followed 
the cell cycle progression under the existence of these 
PGs. As shown in Fig. 3, the accumulation of G1 phase 
cells reached a peak at 24 h, and then it decreased but 
the effect of A12-PGJ2 continued up to 72 h from the 
addition. PGA2 showed the same effect with A12-PGJ2 
0 100 
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Fig. 2. DNA histograms of GOT0 cells without PCs (A) or with 
either 2.5 pg/mJ of A12-PGJ2 (B) or with 7.5 rg/ml of PGAz (C). Data 
shown are representative DNA histograms of two duplicate ex- 
periments. 
up to 36 h, but thereafter Gr phase cells gradually 
decreased to the control level. 
3.2. Effects of PGs on the expression of N-myc 
To investigate the effects of PGs on the expression of 
N-myc, we used exponentially growing cells in the same 
condition which served for cell cycle analysis. Total 
cellular RNA was extracted from each sample and the 
expression of N-myc mRNA was analysed using Nor- 
thern blot analysis described in Materials and Methods. 
As shown in Fig. 4, the expression of N-myc was sup- 
pressed dose-dependently at 24 h after the addition of 
PGs. At the concentration of 2.5 pg/ml, A12-PGJ2 sup- 
pressed N-myc expression to about 40% of the control 
level and at 5.0 pg/ml, Ar2-PGJz almost completely 
suppressed it. In the case of PGA2, the addition of 7.5 
pg/ml caused about 50010 suppression, and at the con- 
centration of 12.5 pg/ml, PGA2 suppressed the expres- 
sion of N-myc almost completely. The expression of ac- 
tin gene as an internal control was not suppressed under 
the same conditions. These findings suggest hat PGs 
selectively suppressed N-myc expression. Fig. 5 shows 
the time course of the expression of N-myc after l-72 h 
from the addition of PGs using the doses of 2.5 pg/ml 
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Fig. 3. Relative ratio of Gr phase cells treated with PGs against con- 
trol cells during continuous exposure to 2.5 pg/ml of Ar2-PGJz (0) and 
7.5 pg/ml of PGA2 (0). Relatives ratios of Gr phase were plotted 
against time. Data represent means of two duplicate experiments. 
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Fig. 4. Effects of PGs on the expression of N-myc. GOT0 cells were 
untreated (a) or treated with 1.25 (b), 2.5 (c), 3.75 (d), and 5.0 (e) 
pg/ml of Al*-PGJ2 and with 7.5 (f), and 12.5 (g) pg/ml of PGA2 for 
24 h, and then Northern blot analysis was performed. 
of A”-PGJz and 7.5 kg/ml of PGA2, The N-myc ex- 
pression was suppressed rapidly to about 20% of the 
control level up to 6 h with both Ai2-PGJ2 and PGAz. 
Then it recovered to about 40% or more, but remained 
at that level with A12-PGJ2, though with PGAz it 
recovered gradually after 24 h and further recovered up 
to about 70% at 72 h. 
4. DISCUSSION 
This is the first report that A12-PGJz, a J series pro- 
staglandin, suppressed the expression of N-myc gene 
which acts in nuclei. Since it has been reported that 
PGAz suppresses the expression of c-myc gene, which is 
also myc gene family oncogene [5], we compared the ef- 
fects of J and A series prostaglandins and found that 
both A12-PGJ2 and PGA2 suppressed N-myc expression 
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Fig. 5. Effects of PGs on N-myc expression during continuous ex- 
posure to 2.5 fig/ml of A.“-PGJr and 7.5 pg/ml of PGA2. (A) shows 
the reoresentative autoradiographs at 12, 24.48, 72 h from the addi- 
tion of PGs (C, control; J, i’*:PGJ2; A, PGAr). The degrees of N- 
rnyc expression are shown in (B) with A”-PGJ2 (0) and PGAz (0). 
They were obtained by densitometric analysis of autoradiographs. 
The percentages of N-myc expression are relative ratios of PGs 
treated cells against control cells at various time points. Data shown 
are means of two experiments. 
and the effect of A12-PGJ2 was longer than that of 
PGAz with equivalent effective doses. J and A series 
prostaglandins have an a&unsaturated carbonyl group 
in the cyclopentenone ring which was reported to be the 
active moiety for cell growth inhibiting activity [ 13,141. 
Though both A’?-PGJz and PGAz have the same reac- 
tive structure, most of PGAz is present as free 
molecules in nuclei. On the other hand, most of 
A12-PGJz binds firmly to nuclear proteins [3]. These 
results suggest hat the modes of binding to cell nuclei 
may reflect on the action of PGs. 
In the present study, we used the equivalent effective 
doses of PGs, which caused the strongest accumulation 
of Gi cells. At higher doses the percentages of Gi cells 
were similar to those of the control. Bhuyan et al. 
reported a similar observation; i.e. PGs caused Gi ar- 
rest of melanoma cells and at higher doses, which 
strongly suppressed the cell growth, no obvious Gi cell 
accumulations were seen [12]. This phenomenon was 
also seen with other substances. Crampton et al. show- 
ed that Didemnin B induced Gi arrest and at higher 
doses it caused ‘frozen’ cell cycle [ 151. These results sug- 
gest the possibility that in the present study the PGs ar- 
rested the cells non specifically in each phase of the cell 
cycle at higher doses, resulted in so called ‘frozen’ cell 
cycle, and thus Gi cell accumulation was not observed. 
We demonstrated that the inhibition of N-myc ex- 
pression by PGs was associated with Gi arrest. The pat- 
terns of the accumulation of Gi phase cells by A12-PGJ2 
and PGAz were similar up to 36 hours from the addi- 
tion. Thereafter the effect of A12-PGJ2 continued up to 
72 h, while that of PGA2 disappeared until 48 h. We 
also showed that the inhibition and the restoration of 
N-myc expression preceded the changes of the cell cycle 
progression. These results indicate that cyclopentenone 
PGs arrest the cell cycle progression of GOT0 cells at 
Gl phase in close association with modulating N-myc 
gene expression through binding to nuclear proteins, 
although the possibility that N-myc gene suppression is 
one of the results led by Gl arresting process triggered 
by PGs is not excluded. 
Recently, A12-PGJ2 is detected in human urine as a 
metabolite of PGD2 [ 161, which raises the possibility 
that A’?-PGJ2 acts on cellular proliferation in some 
physiological conditions. 
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